InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
InflaRx (IFRX) had its price target lowered by Guggenheim from $22.00 to $14.00. They now have a "buy" rating on the stock.
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones